Clinical Research Center of Cape Cod (CRCCC) will provide lung sputum samples for Biomoda’s investigation of its lung cancer detection tool. The technology is designed for cancer screening of large populations at a reasonable cost, Biomoda points out.
The company’s noninvasive sputum assay is being investigated for the early detection of lung cancer. This technology is based on a porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope.
“We are aggressively pursuing internal studies that, coupled with our clinical work with other organizations, will make our assay available to the public in the short term,” according to John Cousins, president of Biomoda. “CRCCC will help make that happen by supplying quality samples in a timely manner.”